|
 |
||
      |
|
|
» Apply for a Grant
- FAQs - Young Investigator - Independent Investigator - Distinguished Investigator - Staglin Award » Grantee List - Young Investigators - Independent Investigators - Distinguished Investigators - Staglin Awards
» Prizes
- Lieber Prize - Falcone Prize - Ruane Prize - Goldman-Rakic Prize - Freedman Award - Klerman Award » For Grantees - Young Investigator Fact Sheet - Independent Investigator Fact Sheet - Distinguished Investigator Fact Sheet - Staglin Award Fact Sheet 
|
 Project Summary  David C. Henderson, M.D. (Young Investigator 2003) of Massachusetts General Hospital, is studying atypical antipsychotic agents (such as clozapine and olanzapine) that have recently been linked to diabetic ketoacidosis and Type 2 diabetes in patients with schizophrenia. Dr. Henderson will conduct an eight-week, double blind, placebo controlled study of rosiglitazone to see whether it improves the insulin sensitivity and glucose utilization associated with clozapine. Multiple risk factors for diabetes will also be examined. Program Area: SCHIZOPHRENIA/PSYCHOTIC DISORDERS\Schizophrenia |
Announcements
NARSAD Award Winners
 Colleen Ann McClung, Ph.D., UT Southwestern Medical Center at Dallas, 2005 & 2007 Young Investigator Latest News from NARSAD
|
